Upper respiratory infections are one of the major reasons for outpatient patient visits to hospitals. Upper respiratory infections occur at the upper region of the respiratory tracts. Particular areas which are primarily affected by the infection include nasal cavity, sinuses, pharynx, and trachea. The Nonprescription Upper respiratory infections drugs are one of the common treatment available in the market. Availability of wide range of medicated products and treatment options are available on the go. Resulting in the OTC medication based market comprising more than 80% of all upper respiratory tract drugs. The wide availability of drugs and comparative low pricing is anticipated drive the Nonprescription Upper Respiratory Infections market. The lenient regulations from the US Food and Drug Administration for OTC drugs is anticipated to lure new manufacturers in the Nonprescription Upper Respiratory Infections market. Additionally, product launches, research, and developments from key manufacturers in Nonprescription Upper Respiratory Infections market are evolving into product segments. Example: - the launch of Otrivin nasal spray (Xylometazoline) from Novartis led to similar product launch from another key market player.
The significantly high incidence of the common cold is one of the prime conditions of the upper respiratory infections, sequentially anticipated to be one of the prime factors for the Nonprescription Upper respiratory infections market growth. Sudden and persistent climate changes coupled with increasing severity of air pollution is anticipated to be one the prime factor increasing the incidence of upper respiratory infection. Thereby increasing URI patient pool and demand for Nonprescription Upper respiratory infections drugs. The higher demand for Nonprescription Upper respiratory infections drugs is primarily arising from developing and developed countries due to growing customs of self-medication. The higher demand is projected to bolster the growth for Nonprescription Upper respiratory infections market. Lifestyle changes and inclination towards personal hygiene is anticipated to boost the demand for preventive treatment drug. Subsequently, aiding the growth for Nonprescription Upper Respiratory Infections market. However, excessive abusive consumption and major adverse effects related to the nonprescription upper respiratory infections drugs is restraining the growth of the nonprescription upper respiratory infections market.
The global Nonprescription Upper Respiratory Infections market is segmented on the basis of Drug Class type, drug form, Route of administration, Distribution Channel, and geography:
The global Nonprescription Upper Respiratory Infections market is extremely fragmented owing to the presence of a high number of manufacturers in the market. As per a private study conducted in the U.S., it is estimated that 1in 4 person is affected from Upper respiratory infection (URI) and is amongst the most probable reason for the physician visits. Thereby, availability of Nonprescription Upper Respiratory Infections drugs is anticipated to increase the market share. The mounting competition in the nonprescription upper respiratory infections market is highly volatile and presence of major global key players is revolutionize the research and development in the manufacturing industry. The penetration of drug distribution channel is widely rooted in the supply of Nonprescription Upper Respiratory Infections drugs, promptly fulfilling the demand from drug stores and pharmacies. Though, there are no any particular medication is available for curing a common cold. All medication prescribed today are used to relive form symptoms. The recent studies and development activities for the dedicated treatment for a common cold is anticipated to boost the nonprescription upper respiratory infections market growth.
Geographically, global Nonprescription Upper Respiratory Infections market is segmented into six key regions viz. North America, Latin America, Europe, the Asia Pacific excluding China, China, and the Middle East & Africa. North America leads the overall Nonprescription Upper Respiratory Infections Market. Adaptive lifestyle changes, an increase in personal care product regimens and reduced government regulations on OTC drugs is anticipated to boost the Nonprescription Upper Respiratory Infections market in North America. Additionally, in the Asia Pacific region, the higher market growth rate is projected due to the increase in increasing practices of self-medication.
Some of the major key players competing in the global Nonprescription Upper Respiratory Infections Market are Pfizer Inc., Alcon, Inc., Collegium Pharmaceutical Inc., Merck & Co. Inc., GlaxoSmithKline plc, Verona Pharma Plc, Teva Pharmaceuticals, Sandoz Inc., Hospira Inc. among others.
The report covers exhaustive analysis on:
Regional analysis includes